Tag #Psychedelics

Showing 1 to 7 of 7 results

theguardian.com

🌐 85% Global Worthiness

Sep 17, 10:18

Philosopher's Psychedelic Journey: From Descartes to Catholicism

Justin Smith-Ruiu, a professor at Université Paris Cité, details his extensive psychedelic drug use in his new book, "On Drugs," arguing that these experiences offer a unique perspective on consciousness and reality, drawing parallels between psychedelics and religious ritual.

Philosopher's Psychedelic Journey: From Descartes to Catholicism

Justin Smith-Ruiu, a professor at Université Paris Cité, details his extensive psychedelic drug use in his new book, "On Drugs," arguing that these experiences offer a unique perspective on consciousness and reality, drawing parallels between psychedelics and religious ritual.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the central argument of Justin Smith-Ruiu's "On Drugs," and what are its potential implications?

Smith-Ruiu argues that psychedelic experiences, by dissolving the self and connecting individuals to cosmic consciousness, offer a unique understanding of reality, challenging traditional Cartesian views that prioritize rationality. This challenges the very foundations of Western philosophy by proposing an alternative path to understanding consciousness.

lexpress.fr

🌐 85% Global Worthiness

Apr 20, 16:11

Israeli Study Links MDMA Consumption to Reduced PTSD Symptoms in Nova Attack Survivors

A study of 657 survivors of the October 7, 2023, Nova festival attack in Israel suggests that MDMA consumption correlated with improved post-trauma social interaction, sleep, and reduced PTSD symptoms compared to other survivors; this finding, while preliminary, could influence PTSD treatments, thou...

Israeli Study Links MDMA Consumption to Reduced PTSD Symptoms in Nova Attack Survivors

A study of 657 survivors of the October 7, 2023, Nova festival attack in Israel suggests that MDMA consumption correlated with improved post-trauma social interaction, sleep, and reduced PTSD symptoms compared to other survivors; this finding, while preliminary, could influence PTSD treatments, thou...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does this study contribute to our understanding of trauma response and potential therapeutic applications of MDMA?

The study, accepted for publication in World Psychiatry, highlights the impact of MDMA on trauma response in a unique mass casualty event. While the study shows a correlation, not causation, it suggests a potential role for MDMA in trauma treatment, opening new avenues in PTSD research. However, the study acknowledges a survival bias, limiting conclusions about the impact on those who perished.

lemonde.fr

🌐 75% Global Worthiness

Apr 7, 13:15

France Explores Psychedelics in End-of-Life Care Debate

France's debate on end-of-life care centers on palliative care and assisted dying, with research on psychedelics like LSD and psilocybine offering potential solutions for alleviating existential anxiety and depression in terminally ill patients; clinical trials are underway, with potential for marke...

France Explores Psychedelics in End-of-Life Care Debate

France's debate on end-of-life care centers on palliative care and assisted dying, with research on psychedelics like LSD and psilocybine offering potential solutions for alleviating existential anxiety and depression in terminally ill patients; clinical trials are underway, with potential for marke...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How does the ongoing research on psychedelics address the limitations of existing treatments for existential anxiety and psychological distress in terminally ill patients?

The debate highlights the limitations of current treatments in addressing existential anxiety and psychological distress in end-of-life care. Research into psychedelics like LSD and psilocybine offers potential solutions, showing efficacy in treating anxiety and depression when administered within a therapeutic medical framework. These substances are undergoing clinical trials in France, with potential for market authorization.

theglobeandmail.com

🌐 % Global Worthiness

Nov 13, 16:05

Psychedelic Drugs: FDA Approvals and Future of Mental Health Treatment

The FDA approval of Cybin's synthetic psilocybin for phase 3 trials, and MindMed's upcoming LSD trials for anxiety, signify progress despite recent setbacks in the psychedelic drug development sector.

Psychedelic Drugs: FDA Approvals and Future of Mental Health Treatment

The FDA approval of Cybin's synthetic psilocybin for phase 3 trials, and MindMed's upcoming LSD trials for anxiety, signify progress despite recent setbacks in the psychedelic drug development sector.

Progress

0% Bias Score

ShareSaveArticle

12345678910

Previous 1 of 10 Next

What recent FDA approval has Cybin Inc. received and what is its purpose?

Cybin Inc. received FDA approval for phase 3 trials of its synthetic psilocybin for major depressive disorder, aiming for results in 2026. This follows setbacks for other psychedelic drug developers, such as Lykos Pharmaceuticals and Compass Pathways.

foxnews.com

🌐 85% Global Worthiness

Jun 7, 13:14

Trump Administration Explores Psychedelics for PTSD Treatment

The Trump administration is exploring the use of psychedelics, such as MDMA and psilocybin, to treat PTSD and other mental health conditions, based on promising clinical trial results and driven by a need for effective alternative treatments; the Department of Veterans Affairs is currently conductin...

Trump Administration Explores Psychedelics for PTSD Treatment

The Trump administration is exploring the use of psychedelics, such as MDMA and psilocybin, to treat PTSD and other mental health conditions, based on promising clinical trial results and driven by a need for effective alternative treatments; the Department of Veterans Affairs is currently conductin...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the Trump administration's approach to using psychedelics for mental health treatment, and what are the immediate implications for veterans?

The Trump administration is exploring psychedelics like MDMA and psilocybin to treat PTSD and other mental health issues, driven by promising clinical trial results showing their effectiveness and safety for veterans and others. The Department of Veterans Affairs is conducting 11 clinical trials involving roughly 800 veterans to assess the therapeutic potential of these substances.

pt.euronews.com

🌐 75% Global Worthiness

Apr 18, 16:13

Microdosing: Placebo Effects and Unproven Benefits

Microdosing, the practice of taking tiny doses of psychedelics like psilocibin or LSD, is gaining popularity as a self-treatment for mental health issues, despite limited scientific evidence and potential risks from unregulated products; while users report benefits, studies suggest placebo effects a...

Microdosing: Placebo Effects and Unproven Benefits

Microdosing, the practice of taking tiny doses of psychedelics like psilocibin or LSD, is gaining popularity as a self-treatment for mental health issues, despite limited scientific evidence and potential risks from unregulated products; while users report benefits, studies suggest placebo effects a...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the potential risks associated with microdosing, and what measures can mitigate these risks?

The perceived benefits of microdosing may stem from the power of belief and expectation. A study showed that participants experienced psychological improvements whether they received microdoses or placebos. This suggests that the placebo effect plays a significant role in the reported benefits, highlighting the need for further controlled studies to disentangle the true effects of the substances themselves.

edition.cnn.com

🌐 85% Global Worthiness

Mar 4, 19:16

Study Links Bad Psychedelic Trips to Increased Mortality Risk

A Canadian study reveals a 2.6 times higher risk of death within five years for individuals experiencing severe adverse reactions to hallucinogens requiring emergency room visits, with suicide being the most common cause of death; the study highlights the potential dangers of unregulated psychedelic...

Study Links Bad Psychedelic Trips to Increased Mortality Risk

A Canadian study reveals a 2.6 times higher risk of death within five years for individuals experiencing severe adverse reactions to hallucinogens requiring emergency room visits, with suicide being the most common cause of death; the study highlights the potential dangers of unregulated psychedelic...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate, specific impact of severe adverse reactions to hallucinogens on mortality rates, based on the recent Canadian study?

A new study reveals a 2.6 times higher risk of death within five years for individuals experiencing severe adverse reactions to hallucinogens requiring emergency hospitalization. This risk is significantly higher than in a comparable group without such incidents. The most common causes of death in this group were suicide, unintentional drug poisoning, respiratory disease, and cancer.

Showing 1 to 7 of 7 results